



PATENT

In the UNITED STATES PATENT and TRADEMARK OFFICE

APPLICANT: Chmura, et al	EXAMINER: Not yet assigned
SERIAL NO.: 10/642,870	ART UNIT: Not yet assigned
FILED: August 18, 2003	DOCKET NO.: 7111.US.01
TITLE: <b>CALCIUM FORTIFIED, SOY BASED, INFANT NUTRITIONAL FORMULA</b>	I certify that this correspondence (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, Alexandria, VA, on the date shown below.
	<u>Wendy Detwiler</u> 10-2403 Wendy Detwiler Date

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed herewith is a Information Disclosure Statement and Form 1449 for the above-referenced patent application. Also enclosed are:

Fifty-five (55) references  
One (1) return postcard

If any fees are owed, or any credit is due pertaining to this case; please charge that fee or apply that credit to Deposit Account No. 01-0025.

Respectfully submitted,

Ross Products Division of  
ABBOTT LABORATORIES  
Department 108140/DS1  
625 Cleveland Avenue  
Columbus, OHIO 43215-1724

William J. Winter  
by William J. Winter  
Reg. No. 36,060

Telephone: 614/624-3012  
Facsimile: 614/624-3074

Docket: 7111.US.01



PATENT

In the UNITED STATES PATENT and TRADEMARK OFFICE

APPLICANT: Chmura, et al.	EXAMINER: Not yet assigned
SERIAL NO.: 10/642,870	ART UNIT: Not yet assigned
FILING DATE: August 18, 2003	DOCKET NO.: 7111.US.01
TITLE: <b>CALCIUM FORTIFIED, SOY BASED, INFANT NUTRITIONAL FORMULA</b>	I certify that this correspondence (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, Alexandria, VA 22313-1450 on the date shown below.
	<i>Wendy Detwiler</i> 10-24-03
	Wendy Detwiler Date

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their duty of disclosure under 37 C.F.R. §1.56, and as authorized and encouraged under 37 C.F.R. §§ 1.97-1.98 and the provisions of MPEP §§ 609 and 707.05(b), Applicants submit herewith certain patent documents, publications and/or other information ("references") which the Patent and Trademark Office may wish to consider in examining the above-identified patent application. The identification of any reference herein is not intended to be and should not be understood as being an admission that such reference necessarily constitutes "prior art" within the meaning of applicable law.

The cited references are listed on attached form PTO-1449.

- ☒ A copy of each cited reference is provided;
- ☐ Copies of cited references are not provided because each has previously been made of record in the parent application, or is otherwise known to be in the Examiner's possession.

The Examiner is requested to review and evaluate each cited reference to make an independent assessment of the materiality of each, if any, to the examination of the above-identified application. The Examiner is requested to ignore any underscoring or highlighting which may have been done because such markings may or may not have any relationship to the subject matter of the present invention. The copies being submitted with this Statement are the best copies available at this time. Applicants respectfully request that (1) the references cited herein be made of record; (2) that the Examiner acknowledge his consideration of each reference by initialing and returning the enclosed copy of the PTO-1449 form; and (3) that such references appear on the printed patent as having been considered on the record.

With regard to payment of a fee:

- ☐ ☒ No fee is due because:
- ☐ ☒ This Statement is mailed within three months of the filing date of this application, or before the mailing date of a first office action on the merits (see 37 C.F.R. §1.97(b)).
- ☐ ☐ Applicants certify that each reference cited in this Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. (see 37 C.F.R. §1.97(e)).
- ☐ ☐ This Statement is filed after the mailing date of a first Office Action on the merits but before the mailing date of either a final action or a Notice of Allowance (see 37 C.F.R. §1.97(c)) so a fee of **\$180.00** is specified by 37 C.F.R. §1.17(p).

If any fees are owed, or any credit is due pertaining to this case, please charge that fee or apply that credit to Deposit Account No. 01-0025.

Ross Products Division of  
ABBOTT LABORATORIES  
Dept. 108140-DS/1  
625 Cleveland Avenue  
Columbus, OHIO 43215-1724


Telephone: (614) 624-3012  
Facsimile: (614) 624-3074

Docket : 7111.US.01

Respectfully submitted,



by William J. Winter  
Reg. No. 36,060



Sheet 1 of 3

FORM PTO-1449 (Rev. 2032)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 7111.US.01	Serial No. 10/642,870
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Chmura, et al	
(Use several sheets if necessary)		Filing Date Aug. 18, 2003	Group

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (if appro.)
	2,732,395	1/24/56	Bolley, et al			
	4,072,670	2/7/78	Goodnight, et al			
	3,736,147	5/29/73	Lacobucci, et al			
	3,733,207	5/15/73	McCabe, et al			
	4,642,236	2/10/87	Friend, et al			
	2001/0018197 A1	8/30/01	Wong, et al			
	2001/0123090 A1	9/5/02	Wong, et al			
	2002/0127288 A1	9/12/02	Wong, et al			
	5,248,765	9/28/93	Mazer, et al			
	5,248,804	9/28/93	Nardelli, et al			
	6,313,273	11/6/01	Thomas, et al			
	2001/0007868 A1	7/12/01	Facchini			
	5,270,450	12/14/93	Westfall, et al			
	4,697,004	9/29/87	Puski, et al			

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Name	Class	Subclass	Translation (Yes No)
EP 380343					
UK 1,574,110					
GB 2,180,241					
JP 50130800					
WO 9830681					
JP 7060635					
WO 200210322					

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Reddy, et al, Adv. Food Res., 28:1-92 (1982)
		Cheryan, CRC Crit. Rev Food Sci Nutri 13:297-335 (1980)
		McKinney, et al, J Biol Chem, 178:117-132 (1949)
		DeRham and Jost., J. Food Sci., 44:596-600 (1979)
		Brooks and Morr, J. Food Sci., 47:1280-1282 (1982)
		Han and Wilfred, J. Agric Food Chem, 36:259-262 (1988)
		Spivey Fox MR, Tas SH: Antinutritive effects of phytate and other phosphorylated derivatives, Nutr Toxicol 3:59-96 (1989)
		Hurrell et al, ; A comparison of iron absorption in adults and infants consuming identical infant formulas, Br J Nutr 79:31-36 (1998)
		Davidson et al., Iron bioavailability studies in infants-the influence of phytic acid and ascorbic acid in infant formulas based on soy isolate, Pediatr Res 36; 6:816-822 (1994)
		Hurrell et al., Soy protein, phytate, and iron absorption in humans, Am J Clin Nutr 1992; 56:573-578
		Lynch et al., Inhibitory effect of a soybean-protein-related moiety on iron absorption in humans. Am J Clin Nutr 1994; 60:567-572
		Rimach et al., Effect of phytic acid and microbial phytase on Cd accumulation, Zn status, and apparent absorption of Ca, P, Mg, Fe, Zn, Cu and Mn in growing rats. Am Nutr Metab 1995; 39:361-370
EXAMINER		DATE CONSIDERED

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 3

FORM PTO-1449 (Rev. 2032)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 7111.US.01	Serial No. 10/642,870
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Chmura, et al	
(Use several sheets if necessary)		Filing Date Aug. 18, 2003	Group

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (if appro.)

**FOREIGN PATENT DOCUMENTS**

Document Number	Date	Name	Class	Subclass	Translation (Yes No)

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

		Pallaf et al., Dietary phytate reduces magnesium bioavailability in growing rats, Nutr Res 1998; 18:1029-1037
		Lonnerdal B: Nutritional aspects of soy formula, Acta Paediatr Suppl 1994;402:105-108
		Quinlan et al, The relationship between stool hardness and stool composition in breast and formula fed infants, JPGN 1995; 20:81-90
		Lasekan et al, Growth of newborn, term infants fed soy formula for one year. Clin Pediatr 1999; 38:563-571
		Ling and Weaver, QJM-Monthly Journal of the Assoc. of Physicians, Vol. 90 (1997)
		Churella HR, Vivian V. The effect of phytic acid in soy infant formulas on the availability of minerals for the rat FASEB J 1976; 35:744
		Graf E, Eaton JW. Effects of phytate on mineral bioavailability in mice. J Nutr 1984; 114:1192-1198
		Ziegler et al. Effect of phytate reduction on mineral absorption from soy-based infant formula. Am J Clin Nutr 1990; 51:528
		Lynch et al., Inhibitory effect of a soybean-protein-related moiety on iron absorption in humans., Am J Clin Nutr 1994 60:567-572
		Reddy et al., The influence of different protein sources on phytate inhibition of nonheme-iron absorption in humans. Am J Clin Nutr 1996; 63:203-207
		Miyazawa et al., Phytate breakdown and apparent absorption of phosphorus, calcium, and magnesium in gerfree and conventionalized rats. Nutr Res 1996; 16:603-613
		Shen et al., An inositol phosphate as a calcium absorption enhancer in rats. J Nutr Biochem 1998; 9:298-301
		Lopez et al., Intestinal fermentation lessens the inhibitory effects of phytic acid ion mineral utilization in rats. J Nutr 1998; 128:1192-1198.
		Lonnerdal et al., Effect of reducing the phytate content and of partially hydrolyzing the protein in soy formula on zinc and copper absorption and status in infant rhesus monkeys and rat pups. Am J Clin Nutr 1999; 69:490-496.
		Van Dael et al., The effect of dephytinization on calcium, copper, iron, manganese, zinc absorption from a soy infant formula. JPGN 1999; 28:595.
		Kennedy et al., Double-blind, randomized trial of a synthetic triacylglycerol in formula-fed infants: effects on stool biochemistry, stool characteristics and bone mineralization, Am J Clin Nutr 1999; 70:920-7.

EXAMINER	DATE CONSIDERED

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

